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We have investigated the anticancer eﬀects of the dietary isothiocyanate sulforaphane (SFN) on colorectal cancer (CRC), using
primary cancer cells lines isolated from ﬁve Taiwanese colorectal cancer patients as the model for colorectal cancer. SFN-treated
cells accumulated in metaphase (SFN 6.25μM) and subG1 (SFN 12.5 and 25μM) as determined by ﬂow cytometry. In addition,
treated cells showed nuclear apoptotic morphology that coincided with an activation of caspase-3, and loss of mitochondrial
membrane potential (ΔΨm). Incubations at higher SFN doses (12.5 and 25μM) resulted in cleavage of procaspase-3 and elevated
caspase-2,-3,-8,and-9activity,suggestingthattheinductionofapoptosisandthesulforaphane-inducedmitosisdelayatthelower
dose are independently regulated. Daily SFN s.c. injections (400micromol/kg/d for 3 weeks) in severe combined immunodeﬁcient
mice with primary human CRC (CP1 to CP5) s.c. tumors resulted in a decrease of mean tumor weight by 70% compared with
vehicle-treated controls. Our ﬁndings suggest that, in addition to the known eﬀects on cancer prevention, sulforaphane may have
antitumor activity in established colorectal cancer.
1.Introduction
Isothiocyanates (ITCs) are natural components of cer-
tain plants and vegetables that have selective biological
activities and functions against carcinogenesis [1, 2], and
many chemopreventive properties have been reported [3,
4]. The use of naturally occurring compounds combined
with chemotherapy might enhance drug sensitivity [5, 6].
Sulforaphane (SFN), a potent cancer preventive agent, is
a dietary isothiocyanate compound found as a precursor
glucosinolate in cruciferous vegetables such as Brussels
sprouts, cauliﬂower, and broccoli [7]. Interest in this agent
has grown in recent years based on its putative beneﬁcial
pharmacological eﬀects, which include antioxidant [8], anti-
inﬂammatory [9], and antitumor properties [10, 11]. It
has been discovered that SFN is also a potent scavenger
of reactive oxygen species (ROS), including superoxide
anions and hydroxyl radicals [12, 13]. Moreover, there
have been some indications that SFN may help in the
prevention and treatment of patients with oxidative damage
and suppress the speciﬁc inﬂammatory factors [14, 15].
Many studies indicate a positive correlation between the
consumption of cruciferous vegetables and the decreased
incidence of some tumors including prostate [16], cervical2 Evidence-Based Complementary and Alternative Medicine
[17], ovarian [18], lung [19], and gastrointestinal tract [20,
21]. In addition to the actions of inhibiting cell proliferation
and increasing apoptosis [22], other mechanisms have also
been proposed to rationalize the anticarcinogenic eﬀect
of SFN, such as the anti-inﬂammatory and antioxidant
activities, the induction of phase-II detoxiﬁcation enzymes,
the inhibition of cyclooxygenase 2 (COX-2) [23], the eﬀect
on NFκB transcription factors [24], the inhibition of matrix
metalloproteinase (MMP), the eﬀect on protein kinases, and
others [25, 26].
Eﬀects of SFN on ﬁve established human primary cell
lines (CP1 to CP5) were investigated in this study. In this
paper, studies have been initiated to investigate whether the
SFN could contribute to the antiproliferation and apoptosis
of the primary cancer cells isolated from the colorectal
cancer patients. The aims are to investigate whether the
antiproliferation and apoptosis activities of SFN on the
primarycoloncancercellscouldbeexplained.Weexpectthat
all of these experiments could provide a scientiﬁc basis and
technical support for CRC therapy.
2.MaterialsandMethods
2.1. Materials. Sulforaphane [1-isothiocyanato-(4R,S)-
(methylsulﬁnyl)butane], DMSO (dimethyl sulfoxide), and
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] were obtained from Sigma (St. Louis, MO). Cell
culture medium (DMEM), fetal bovine serum, antibiotics,
sodium pyruvate, trypsin, and phosphate-buﬀered saline
(PBS) were purchased from Gibco, BRL (Grand Island, NY).
Polyvinylidene ﬂuoride membrane (PVDF) (Millipore) and
molecular weight markers were purchased from Bio-Rad
(USA). All other reagents and compounds were analytical
grades.
2.2. Cell Culture. The ﬁve primary cell lines of colon cancer
cells were derived, as a gift, from the cell bank maintained
in the MedicoGenomics Research Center at KMU [27, 28].
The cells were grown at 37◦C in Dulbecco’s Modiﬁed Eagle
Medium (GibcoBRL) supplemented with 10% (v/v) Fetal
Bovine Serum (HyClone) and a combination of antibi-
otics (penicillin, 200unit/mL, and streptomycin, 200g/mL)
(HyClone) under an atmosphere CO2/air (5%) this series of
studies.
2.3. Cell Proliferation Assay. The cells were seeded into 96-
well culture plates at 5000cells/well. The cells were treated
with 0, 6.25, 12.5, 25, and 50μMS F Nf o r1t o4d a y s .
MTT dye (1mg/mL) was added to each well for at least 4
hoursoftreatment.Thereactionwasstoppedbytheaddition
of DMSO, and optical density was measured at 540nm
on a multiwell plate reader. Background absorbance of the
medium in the absence of cells was subtracted. All samples
were assayed in triplicate, and the mean for each experiment
was calculated. Results were expressed as a percentage of
control, which was considered as 100%. Each assay was
carried out in triplicate, and the results were expressed as the
mean (±SEM).
2.4. Cell Cycle Analysis. The method for cell cycle analysis
using propidium iodide (PI) is using the ﬂuorescent nucleic
acid dye PI to identify the proportion of cells that are in one
of the three interphase stages of the cell cycle. The cells were
treated with 0, 6.25, 12.5, and 25μMS F Nf o r2 4h o u r s .C e l l s
were harvested and ﬁxed in 1mL cold 70% ethanol at least
8h o u r sa t−20◦C. DNA was stained in PI/RNaseA solution,
and the cell cycle (At least 10,000 single cells) was detected
by ﬂow cytometry (FACSCalibur, BD). Data was analyzed by
WinMDI 2.8 free software (BD, USA).
2.5. Evaluation of Apoptosis. The apoptosis was assessed by
the ApopNexin FITC apoptosis detection kit (Chemicon,
USA). The cells were treated with 0, 6.25, 12.5, and 25μM
SFN for 6 hours, and the apoptotic cells were detected by
ApopNexin FITC apoptosis detection kit and ﬂow cytometry
(FACSCalibur, BD) and data analyzed by WinMDI 2.8 free
software (BD, USA).
2.6. Evaluation of Mitochondrial Membrane Potential (MMP;
ΔΨm). The cells were ﬁrst seeded in 24-well plates (Orange,
UK). Following the treatment with SFN for 6 hours, JC-1
(10μg/mL, Sigma, USA) was added to the culture medium,
50μL per well, and then incubated (at 37◦C for 20min)
for mitochondria staining. After washing twice with a
warm PBS, the cells were ﬁxed with 2% paraformaldehyde,
inspected by Flow cytometry (FACSCalibur, BD) and data
analyzed by WinMDI 2.8 free software (BD, USA).
2.7. Western Blot Assay. A total of 30–50μg proteins were
separated by SDS-PAGE (10–12% SDS-polyacrylamide gel
electrophoresis) and transferred to PVDF membranes (Mil-
lipore, USA) in a tank blotter (in 25mM Tris/0.192M
glycine, pH 8.3/20% methanol) at 30 voltage overnight.
The membranes were blocked with 5% nonfat milk (in
10mM Tris-HCl, pH 8.0/150mM NaCl/0.05% tween-20)
overnight and incubated with anti-β-actin (AC-15 Sigma,
USA), anti-Caspase 3 (SC-7148 Santa Cruz, USA) antibody
for 1.5∼2 hours. The blots were washed with Tris-HCl (pH
8.0/150mM NaCl/0.05% Tween-20) for 3 × 10 minutes and
incubated with second antibody (antirabbit or antimouse
immunoglobulins) (IRDye Li-COR, USA) at 1/200 dilution
for 1 hour. The antigen was then visualized and analyzed by
Odyssey infrared imaging system (Odyssey LI-COR, USA).
2.8. Caspase Activity Assay. The caspase (2-, 3-, 8-, and
9-) activity was assessed by the ApoAlert Caspase assay
plates (Clontech, USA). The cells were treated with SFN
of 0, 12.5, and 25μM with or without caspase-speciﬁc
inhibitor for 8 hours. The caspase activity was detected
by ApoAlert Caspase assay plates and inspected by the
BioTek FLx800 TBI reader (Bio-Tek, USA). The plates
contained the ﬂuorogenic substrates and inhibitors speciﬁc
for diﬀerent caspases. These substrates were covalently
linked to their respective activated caspases. The substrates
were covalently linked to the ﬂuorogenic dye 7-amino-4-Evidence-Based Complementary and Alternative Medicine 3
methyl coumarin (AMC). Peptide-bound AMC excites in
the UV range (380nm) and emits at 460nm. The AMC
was normalized by total protein, and each assay was carried
out in triplicate, and the results were expressed as the mean
(±SEM).
2.9. Confocal Microscopy of NF-κB Subunit p50 Activity.
Confocal microscopy was performed as described pre-
viously. Brieﬂy, the CRC cells (2 × 106 cells) were
treated with 0 and 25μMS F Nf o r1 6h o u r sa n dw e r e
ﬁxed on coverslips. After treatment, they were incu-
bated with rabbit antihuman p50 antibody (SC-8414
PE, Santa Cruz Biotechnology) for 30 minutes and
then washed with PBS. The cells were mounted onto
microscope slides using mounting medium containing
DAPI.
2.10. DNA Fragmentation Assay. The DNA fragmentation
was detected by ApoAlert DNA fragmentation assay kit
(Clontech, USA). The assay is based on terminal deoxynu-
cleotidyl transferase-(TdT-) mediated dUTP nick end label-
ing (TUNEL). TdT catalyzes incorporation of ﬂuorescein-
dUTP at the free 3 -hydroxyl ends of fragmented DNA. The
cells were treated with SFN for 24 hours, and the ﬂuorescein-
labeled DNA was detected via ﬂow cytometry (FACSCalibur,
BD, USA) and data analyzed by WinMDI 2.8 free software
(BD, USA).
2.11. Tumor Xenograft Animal Model. Experiments were
done on male severe combined immunodeﬁcient (SCID)
mice (National Laboratory Animal Center, Taipei, Taiwan)
according to the regulation of the Institutional Animal Care
and Use Committee (IACUC, CJCU-98-006). CRC (CP1 to
CP5) tumors for implantation were initially grown from
injections of CRC cell lines (200μLo f3× 106 cells) at
the s.c. abdomen site. Tumor cells were implanted at the
same site into an experimental animal at the age of 6 weeks.
After 21 days of tumor establishment in severe combined
immunodeﬁcient mice, at the start of the exponential tumor
growth phase, animals were randomly divided into the
treatment groups (n = 3). Each animal received i.p. injection
(200μL) either PBS (vehicle control) or SFN (200μMa n d
400μM)daily,includingweekends,for3weeks.Animalbody
weight and tumor size were measured and recorded. Results
were expressed as a percentage of vehicle control, which was
considered as 100%. Each assay was carried out in triplicate,
and the results were expressed as the mean (±SEM).
2.12. Statistical Analysis. All data were reported as the means
(±SEM) of at least three separate experiments. Statistical
analysis was using t-test, with the signiﬁcant diﬀerences
determined at the level of P<0.05.
3. Results
3.1. SFN Inhibits the Cell Survival/Proliferation of Five
Primary CRC Cell Lines. We hypothesized that SFN could
mediate the survival of primary colorectal cancer cell lines
andthusinhibittheirproliferation.Toexplorethisantitumor
activity of SFN against the CRC cells, an in vitro study was
initiated by treating each of the CRC cell lines to increasing
doses of SFN (0, 6.25, 12.5, 25, and 50μM) for 24 hours.
The proliferation of these SFN-treated cancer cells was then
measured by MTT method. The results summarized in
Figure 1(a) indicate that the survival and proliferation of
the primary colon cancer cells both decrease per increase
of the dose of SFN added into the cell culture, which show
ad o s e - d e p e n d e n tr e d u c t i o n( y =− 12.3x + 114.65 R2 =
0.9892).Moreover,SFNwasnotedtoinduceamorphological
change in the primary colon cancer cells. A microscopic
examination showed that following the exposure to SFN
(25μM)for6to24hours,theprimarycoloncancercellshave
displayed a remarkable change in their morphology and SFN
induced the death of cancer cells, which formed a suspension
in the medium (data not shown).
3.2. Growth-Inhibitory Eﬀect of SFN Is Partially Irreversible.
To study whether the growth-inhibitory eﬀect of SFN is
reversible, the primary colon cancer cells were recultivated
in a fresh culture medium, after their exposure to SFN
(12.5μM) for 24 hours, and the recovery of cell proliferation
was then assessed for an additional 24 to 72 hours and
analyzed by the MTT assay. The results in Figure 1(b)
suggest that the cancer cells have substantially lost their
ability to proliferate (y =− 18.495x + 112.83 R2 = 0.9393)
following the SFN treatment for 24 hours. The observations
could imply that the primary colorectal cancer cells have
undergone an irreversible change, such as apoptosis, at least
to a partial extent.
3.3. Sulforaphane Inhibits Colony Formation in Human CRC
Cells. We next examined the eﬀects of SFN on colony
formation (a characteristic of cancer) on ﬁve CRC cell lines
by soft agar assay. SFN inhibited colony formation in a dose-
dependent manner (Figure 1(c)). Colonies formed by CRC
cells were sensitive to SFN. These data suggest that SFN can
be used as a potent chemopreventive agent for CRC therapy.
3.4. SFN Treatment Induces Cell Cycle G2/M Arrest and Accu-
mulated Sub G1 in CRC Cell Lines. Cell cycle distribution of
SFN-treated CRC cell lines was analyzed by ﬂow cytometry,
aiming to determine whether the inhibitory eﬀect was due
to cell cycle arrest and apoptosis. Before being processed
and analyzed, both kinds of cells were exposed to SFN for
a total of 24h. As shown in Figure 2(a), the CRC cells
exposed to SFN 6.25μM showed G2/M arrest, but SFN 12.5
and 25μM showed increase in the number of cells in the
sub G0/G1 phase, as compared with that of the untreated
cells. These results revealed that SFN could hold up CRC
cell line proliferation via caused cell cycle arrest in the G2/M
phase and a signiﬁcant increase in the proportion of cells in
the sub G0/G1 phase. The results in Figure 2(b) suggest that
the ﬁve CRC cell lines have accumulated sub G0/G1 phase
(y = 11.602x − 12.985 R2 = 0.9139) following the SFN4 Evidence-Based Complementary and Alternative Medicine
treatment for 24 hours. The observations could imply that
theprimarycolorectalcancercellshaveundergoneapoptosis.
3.5. Apoptosis of CRC Cell Lines Induced by SFN. Detection
between the intact cells, early apoptotic cells, and late
apoptotic cells or dead cells could be carried out with PI-
annexin-V double staining; thus, we performed this assay
to further explore cell apoptosis. To explore the potential
role that SFN could play in the apoptosis of CRC cells,
the ApopNexin FITC apoptosis detection kit has been used
to identify the formation of apoptotic cells in the ﬁve CRC
cell lines after the 6 hours of exposure to SFN. A typical set
of results for the ApopNexin FITC apoptosis detection kit
is illustrated in Figure 3(a), in which the annexin V-FITC
deposits are indicative of the positive existence of apoptotic
cells. A dose-dependent increase in apoptosis was observed
(y = 17.62x − 14 R2 = 0.9654), that is, the higher the dose
of SFN (6.25, 12.5 and 25μM) used in the exposure, the
greater the extent of apoptosis (Figure 3(b)). The increase of
the percentages of apoptotic CRC cell lines was observed in
all the doses after treatment for 6h. In 6h, approximately
4.6 + 0.6% of ﬁve CRC cells were totally apoptotic (early
apoptosis and late apoptosis) cells in control. The rate of
apoptotic CRC cells increased to 22.9 + 6.5% with 6.25μM
SFN treatments. When the concentrations of SFN increased
to 12.5 and 25μM, the percentages of total apoptotic CRC
cells increased to 32.6 + 8.9% and 60.1 + 21.3%, respectively.
Taken together, the observations imply that the apoptosis of
CRC cell lines is signiﬁcantly elevated by SFN.
3.6. Assessment of Changes in Mitochondrial Membrane
Potential. The loss of mitochondrial membrane potential
is a hallmark for apoptosis. It is an early event coinciding
with caspase activation. In nonapoptotic cells, JC-1 exists
as a monomer in the cytosol (green) and accumulates
as aggregates in the mitochondria, which appear red. In
apoptotic and necrotic cells, JC-1 exists in monomeric form
and stains the cytosol green. Figure 4(a) shows typical FL-
1/FL-2 dot plots for JC-1 staining CRC cell lines with and
without apoptosis. SFN-free CRC cell lines are without
apoptosis,whichhaveredﬂuorescingJ-aggregates.Thegreen
ﬂuorescing monomers shown in the lower part indicate
apoptotic cell lines (SFN 6.25, 12.5, and 25μMt r e a t m e n t ) .
Figure 4(b)showsthepercentagesofapoptoticCRCcelllines
analyzed by ﬂow cytometer in diﬀerent SFN-treated groups.
The x-fold increase of mitochondrial membrane potential
lost was observed in all the doses after treatment for 6h.
In 6h, the folds increased to 1.8 + 0.6 with 6.25μMS F N
treatment. When the concentrations of SFN increased to
12.5 and 25μM, the folds raised to 2.3 + 0.9 and 3.5 +
0.5, respectively. Taken together, the observations imply that
SFN has signiﬁcantly reduced the mitochondrial membrane
potential of CRC cell lines.
3.7. SFN Inhibits Nuclear NF-κB Transcription Factor Activity
in CRC Cell Lines. With ﬁnding functional changes and
increased apoptosis of SFN in CRC cell lines, the NF-κB
activity of SFN-treated CRC cell lines was examined. NF-
κB is a transcription factor regulating DC function and
apoptosis. NF-κB is inactive in the cytoplasm, as it binds to
the protein inhibitor IκB. Following the degradation of IκB,
NF-κB p50/52 translocates into the nucleus and binds to its
speciﬁc target DNA sequence. To explore the potential role
that SFN inhibits nuclear NF-κB transcription factor activity
of CRC cell lines, confocal microscopy was used to identify
the activity of NF-κB transcription factor in the CRC cell
lines after the 16 hours of exposure to SFN. The results
summarized in Figure 5 indicate that less NF-κB subunit
p50/52 was observed in the nuclei of CRC cell lines treated
with SFN 25μM than in the nuclei of SFN-free CRC cell
lines. This could imply that the primary colorectal cancer
cell lines have repressed activity of NF-κB as per increasing
the dose of SFN added into the cell cultures.
3.8. Apoptosis Induction by SFN in CRC Cell Lines via
Caspase Activation. Figure 6(a) shows the immunoblotting
of cellular proteins from ﬁve CRC cell lines treated with
SFN showing decrease of procaspase-3 after SFN incubation.
Quantiﬁcation of procaspase-3, done by measuring the rel-
ative band intensities, showed that procaspase-3 levels were
signiﬁcantly lower in cells incubated with SFN (Figure 6(b)).
The results indicated that SFN induced caspase-3 activity
viacleavedprocaspase-3and apoptosis afterSFNincubation.
As shown in Figure 6(c), the SFN elevated caspase-2, -3, -8,
-9 activities in ﬁve CRC cell lines that have been decreased
with caspase-speciﬁc inhibitors. The results summarized in
Figure 6 indicate that the increased levels of caspase activity
may play an important role in SFN-induced apoptosis in
CRC cell lines.
3.9. SFN-Induced DNA Fragmentation in CRC Cell Lines.
Cells undergoing apoptosis will lose part of their DNA (due
to the DNA fragmentation in later apoptosis) [29]. It is
hypothesized that SFN could induce apoptosis of CRC cell
lines via DNA fragmentation. To explore this eﬀect of SFN
against the ﬁve CRC cell lines, an in vitro study was initiated
by treating each of the cell lines with SFN for 24 hours. The
quantiﬁcation of DNA fragmentation was measured by the
ﬂuorescence intensities from ﬂow cytometry (Figure 6(d)),
showing that DNA fragmentation levels were signiﬁcantly
increased in cells incubated with SFN. Taken together, the
observations imply that SFN has signiﬁcantly induced the
DNA fragmentation of CRC cells.
3.10.SFNInhibitsTumorGrowthinSCIDMice. Macroscopic
tumors were observed on day 21, after injection of SFN
and PBS control groups of nude mice. After injection of
SFN 400μM in the experimental group, tumors developed
slowly. After 21 days of injection of SFN, no mice had
died in the three groups, and the tumors were resected
and measured. Small pale tumor nodules were observed
in the tumors, whereas red and hypervascularized large
tumors were present in the PBS control and SFN 200μM
tumor cells. The average size of tumors in the experi-
mental group (400μM) was 52.99% (tumor image size)Evidence-Based Complementary and Alternative Medicine 5
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Figure 1: (a) Sulforaphanemediates thesurvival ofﬁve human primarycolorectal cancer (CRC)cell lines(ﬁve groups, n = 6 per group) and
thus inhibits their proliferation. In vitro study was initiated by treating each of the cell lines to the increasing doses of SFN (0, 6.25, 12.5, 25,
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of cancer cells. The survival of these SFN-treated CRC cells was then measured by MTT method. (c) Eﬀect of SFN on colony formation. CRC
cells were treated with SFN, and number of colonies was counted. Results were expressed as a percentage of control, which was considered as
100%. All data were reported as the means (±SEM) of at least three separate experiments. Statistical analysis used the t-test, with the
signiﬁcant diﬀerences determined at the level of
∗P < 0.05 versus time 0 group, while the symbol on the bar denotes the diﬀerence which is
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Figure 3: Apoptosis of CRC cell lines induced by SFN. Flow cytometric analysis of PI-Annexin-V to quantify SFN-induced apoptosis in
CRC cell lines. (a) Dot plots of ﬁve CRC cell lines with SFN treatment at 0, 6.25, 12.5, and 25μM for 6h. (b) Results were expressed as a
percentage of total apoptosis cells (early and late apoptosis).8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Reduction of the mitochondrial membrane potential (ΔΨm) in the CRC cell lines by SFN, which was determined by JC-1 staining
and detected by the ﬂow cytometry. (a) Dot plots of ﬁve CRC cell lines with SFN treatment at 0, 6.25, 12.5, and 25μMf o r6h .( b )T h e
reduction of the (ΔΨm) containing polarized or depolarized mitochondria determined the ratio of the two ﬂuorescence intensities analyzed
by ﬂow cytometry. All the data shown are the folds of ﬁve CRC cell lines. The symbol (∗) on each group of bars denotes that diﬀerence from
the treatment with 0μM SFN is statistically signiﬁcant at P<0.05.Evidence-Based Complementary and Alternative Medicine 9
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Figure 5:DiminishedNF-κBactivityinSFN-treatedCRCcelllines.
Five CRC cell lines were examined for their NF-κBa c t i vi t y1 6h o u r s
after SFN stimulation by confocal microscopy of NF-κB subunit
p50/52 localization. The CRC cell lines were stained for p50/52
(red). DAPI (blue) indicates nucleus, where active form of NF-κB
subunit p50/52 is found.
and 28.70% (tumor weight), much less than the average
size of the PBS control (100%) (Figure 7(b)). The results
indicated that SFN could decrease tumorigenesis by inhibit-
ing neovascularization in tumors in vivo. SFN might also
have inhibitory actions on surrounding tumor tissues and
indirectly inhibit tumorigenesis (Figure 7(a)).
4. Discussion
Sulforaphane (SFN), a naturally occurring alkyl isothio-
cyanate, has been shown to be a more potent cytotoxic
agent than other synthetic analogues isothiocyanates (ITCs)
in cancercells [30]. In a previous study, sulforaphane-treated
cells showed growth arrest and cell cycle G2/M accumulation
[31]. However, this eﬀect seemed to be independent of a
DNA damage Chk1-cdc2-mediated pathway, unlike the G2
arrest mediated by radiation, and seemed to be predom-
inantly a metaphase arrest [32]. The eﬀects of SFN may
occur by the disruption of microtubules, whereupon it is
expected that the activity of the mitotic spindle checkpoint is
maintained and arrests cells in metaphase [33]. Of interest,
our ﬁndings suggest that cell cycle G2/M arrests at the
low SFN doses (6.25μM), whereas apoptosis and caspase
activation dominate at the higher doses (12.5 and 25μM) in
ﬁve CRC cell lines. The results of mechanical analysis have
led us to conclude that both the inhibition of proliferation
and the induction of apoptosis are highly dependent upon
the SFN. However, on further investigation, our data suggest
a more complex mechanism involving cell cycle deregulation
and apoptosis that seems to reﬂect diﬀerences in degree of
SFN-induced toxicity between the CRC cell lines.
The most common cell death mode on SFN treatment
seems to be apoptosis [22]. Two major apoptotic pathways
exist: the death receptor and the mitochondrial pathways
[34]. Multiple apoptotic stimuli trigger the activation of
proteases called caspases, which in turn initiate and execute
the apoptotic program [35]. One of the hallmarks of the
terminal stages of apoptosis is internucleosomal DNA break-
down, which was ﬁrst recognized in [36]. Recent studies
have led to the discovery of two major apoptotic nucleases,
termed DNA fragmentation factor (DFF) [37] or caspase-
activated DNase (CAD) [38], and endonuclease G. Both
endonucleases attack chromatin to yield 3-hydroxyl and 5-
phosphatetermini,ﬁrstcreating50-to300-kbcleavageprod-
ucts and then oligonucleosomal fragmentation, but these
nucleases show diﬀerent cellular locations and are regulated
in fundamentally diﬀerent ways. Although activation of the
executorial caspases seems to be indispensable for realization
of the apoptotic program, several forms of cell demise have
beenshowntobecaspaseindependentorevenacceleratedby
caspaseinhibitors[39].Inapreviousstudy,theSFNactivated
the caspase-8-dependent death receptor pathway, coinciding
with the activation of the mitochondrial pathway [40].
Activation of caspase-8 can cleave the BH3 family member
Bid [41]. Truncated Bid then migrates to the mitochondria,
leading to the loss of MMP, cytochrome c release, and
activation of the initiator caspase-9 [42]. The observations of
thisstudyhaveimpliedthatSFNhassigniﬁcantlyinducedthe
caspase-3 activity of CRC cell lines. Caspase-3-like activity
and plasma membrane disintegration served as measures
of early apoptosis whereas nuclear fragmentation served as
indicator of late apoptosis events [29].
Nuclear factor κB( N F - κB) plays an important role in
inﬂammation, autoimmune response, cell proliferation, and
apoptosis by regulating the expression of genes involved
in these processes [43]. Active NF-κB is most commonly
composed of the heterodimer DNA-binding subunits p50
and p65. It has recently been shown that inactivation of p65
subunit of NF-κB leads to the death through apoptosis of
liver cells [44]. Similarly, it has been shown in a wide range
of cells that when NF-κB has been inactivated by Iκ-Bα,c e l l s
were more sensitive to TNF-α-induced apoptosis. Evidence
exists for NF-κB playing both anti- and proapoptosis roles
[45]. The reducing levels of NF-κB may be involved in SFN-
induced apoptosis of CRC cells.10 Evidence-Based Complementary and Alternative Medicine
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Figure 6: SFN activates procaspase-3 degradation in ﬁve CRC cell lines. The cells were treated with SFN (0, 6.25, 12.5, and 25μM) for
24 hours, and then Western blot analysis was performed for procaspase-3. (a) Representative blot from 3 independent experiments. (b)
Quantiﬁcation of band intensities by Li-COR near infrared imaging system. (c) The caspase-2, -3, -8, -9 activity was analyzed by ApoAlert
Caspase assay plates. SFN induces the caspase activity of ﬁve CRC cell lines. (d) Quantiﬁcation of DNA fragmentation by measuring the
ﬂuorescence intensities by ﬂow cytometry. The data showed that DNA fragmentation levels were signiﬁcantly elevated in cells incubated
with SFN incubation for 24 hours. All data were reported as the means (±SEM) of ﬁve CRC cell lines. Statistical analysis used the t-test, with
the signiﬁcant diﬀerences determined at the level of ∗P < 0.05 versus 0μM control group.Evidence-Based Complementary and Alternative Medicine 11
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Figure 7: SFN inhibits in vivo t u m o rg r o w t h .( a )E ﬀects of SFN on tumor growth of SCID mice subcutaneously inoculated with primary
human CRC cell lines. The results showed that SFN 400μM inhibited tumor growth signiﬁcantly in both cancer xenografts. (b) Inhibition
of tumor growth was compared among tested groups. The inhibitory ratio was normalized to the negative control (PBS group) (values
represent percent of control, n = 3 ∗P<0.05 versus PBS group).
Recent studies have shown that SFN inhibited growth
of tumor precursors [46] and growth of tumors in mice
models when treatment was started at the time of carcinogen
administration [47]. The inhibition of PI3K/AKT and ERK
pathways acts together to activate FOXO transcription factor
and enhances SFN-induced FOXO transcriptional activity,
leading to cell cycle arrest and apoptosis [48]. We now
show that growth of established s.c. CRC tumor xenografts
was suppressed by SFN treatment. Sulforaphane and related
isothiocyanate compounds should therefore be investigated
further as antitumor agents in addition to their established
eﬀects in cancer prevention.
In conclusion, we have demonstrated that SFN inhibits
tumor growth by inducing caspase and mitochondrial
pathway apoptosis and by arresting the cell cycle at G2/M
phase. Our results show that SFN might be an eﬀective
anticancer drug for cancer therapy and provide preliminary
basisforitsclinicalapplication. However,furtherworkisstill
needed to separate its bioactive components for further drug
development.
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